OXFORD, UK, September 17th, 2014

PharmaVentures is pleased to announce that it has acted as advisor to MedGenesis Therapeutix, Inc. (MedGenesis) in their recently announced agreement with Pfizer. MedGenesis’ unique therapeutic approach, which will be used in the clinical development of potential treatments for Parkinson’s disease, delivers GDNF (glial cell-derived neurotrophic factor) precisely to the regions of the brain where it is required via its convection enhanced delivery (CED) technology.

MedGenesis, a Canadian biotechnology company, has adapted the CED approach to enable unprecedented precision in delivery of drugs to predefined areas of the brain. Delivering GDNF to people with Parkinson’s disease in this way offers the possibility of treating the underlying disease rather than just the symptoms.

Adrian Dawkes, Vice President, who led the PharmaVentures team on the deal commented: “We are delighted to have worked with MedGenesis in partnering with one of the world’s leading pharmaceutical companies to complete development and commercialisation of the GDNF treatment. The CED technology could represent a paradigm shift in the treatment of Parkinson’s and many other neurological diseases“.

Fintan Walton, Chief Executive, PharmaVentures, Ltd added: “PharmaVentures has a strong history in assisting companies in licensing but this agreement is quite special as it creates an exciting and unique partnership for the potential treatment of this debilitating disease “.

  – ends –

OXFORD, England, September 16^th 2014

PharmaVentures is pleased to announce the appointment of Dr Christopher Berry, formerly of Sanofi’s R&D Transactions Group, as an Associate in the corporate advisory team. Based in Paris, France, Dr Berry has negotiated 56 signed deals since 2010. Partners included universities, biotechnology companies and large pharmaceutical companies.

Dr Berry was responsible for building research collaborations in the areas of anti-infectives, biologics and regenerative medicine, as well as for the Asia-Pacific Therapeutic Unit. He was previously Head of Thrombosis and Haematology in Synthélabo Recherche, one of Sanofi’s predecessor companies. Dr Berry holds a PhD in Pharmacology from King’s College, London and an MBA from the Open Business School and is a fluent French speaker.

 Dr Fintan Walton, CEO, PharmaVentures said “We are delighted to have Dr Berry join us. His vast experience in early stage deal making will compliment our existing team and enable us to continue to offer our clients expert help throughout their deal making processes”.

 Dr Christopher Berry commented “Early stage deal making is essential as pharmaceutical companies strive to build competitive pipelines”.

 – ends –

OXFORD, UK, August 27^th, 2014

PharmaVentures is pleased to announce that it acted as exclusive advisor on the sale of Medical Insight, the Danish enterprise imaging software company, to Karos Health, based in Ontario, Canada. The sale was completed in June and announced yesterday by Karos Health.

PharmaVentures CEO, Dr Fintan Walton said, “We are delighted to have been advisors to Medical Insight in this important sector.  This success follows a string of recent global M&A deals advised by us including the recent sale of a biologics manufacturing facility in the US on behalf of a major US pharmaceutical company.”

Ping Shek, PharmaVentures’ lead advisor on the transaction added ‘Inter-operability and cross-enterprise workflow solutions, as well as mobility, are increasingly important components in the delivery of healthcare services such as diagnostic imaging services.  Software and ICT groups in healthcare are increasingly looking to acquire businesses in these areas where they can play strategically into their customer network’.

– ends –

OXFORD, UK, July 7th, 2014

PharmaVentures is pleased to announce that it has acted as advisor to one of the top 10 Pharma companies in its divestment of a manufacturing facility in North America. The deal, finalised in May, represents a significant success for the major Pharma in implementing its forward strategy and the acquisition of a growth driving capability for the acquirer. This divestment follows multiple divestments of R&D and Manufacturing facilities in the last 4 years for several of the largest pharmaceutical companies.

Fintan Walton, CEO, PharmaVentures Ltd commented: “Once again PharmaVentures is delighted to have delivered a successful and valuable outcome for our client and in the process secured hundreds of jobs.”

Over the past 22 years, PharmaVentures has acted as advisor to over 600 global pharmaceutical and biotechnology clients in transactions covering licensing, merger, acquisition, divestment and joint venture activities for companies.

– ends –

OXFORD, UK, May 21st, 2014

PharmaVentures is pleased to announce the appointment of Latin American expert Valeria Uribe as associate to significantly enhance the global reach of the Corporate Advisory team. 

A dynamic professional with formal education in Medical Sciences and international experience in business development in the pharmaceutical and biotechnology industry, Valeria brings knowledge in developing and commercializing products and technologies in Latin America and worldwide.

Valeria received her graduate degree from the University of British Columbia, while conducting research in Dr. Michael Hayden’s laboratory, where she worked on target validation in Huntington Disease. She obtained her bachelor´s degree cum laude with distinction in Cognitive Neuroscience from Boston University.

OXFORD, UK, May 12th, 2014

PharmaVentures is pleased to announce that it has been engaged by Tiziana Life Sciences, Plc. to provide independent valuation advice for assets acquired as part of it’s successful admission onto London Stock Exchange’s AIM in April 2014.

Tiziana Life Sciences, is a London, England based company founded in 2013 with a mission to discover and develop novel molecules that inhibit BCL3 – a gene that is involved in cell motility in metastatic cancers. There is a large unmet need for targeted therapeutics for late-stage breast cancer, which currently has very low survivability – more than 92% of Stage 4 / metastatic cancer patients die within 5 years of diagnosis.

Fintan Walton, CEO, PharmaVentures Ltd said:

“PharmaVentures is delighted to have conducted this critically important independent valuation for the second bio-pharmaceutical company this year to join the London Stock Exchange.”

Over the past 22 years, PharmaVentures has acted as advisor to over 600 global pharmaceutical and biotechnology clients in valuations and transactions covering licensing, pharma mergers, acquisitions, divestments and joint venture activities for companies.